Abbott Laboratories Pakistan Limited · PSX:ABOT
Abbott Laboratories Pakistan — Investor Presentation (May 2026)
22 slides from Abbott Laboratories Pakistan's investor presentation, May 25, 2026
Slide 1: Corporate Briefing Session
Corporate Briefing Session 25 | may | 2026
Slide 2: Table of Contents
Table of Contents Core Values and History Financial Performance Snapshot Business Performance 2 Awards and Recognitions Future Outlook Q&A
Slide 3: Our Core Values and History
Our Core Values A and History FS Cc) ABBOTT
Slide 4: Core Values
Core Values We see needs first and deliver game-changing solutions. We create new technologies and products to PIONEERING help people live fuller lives through better health, and we bring that same spirit of innovation to everything we do as a company. ACHIEVING We focus relentlessly on delivering f
Slide 5: History of Major Events
History of Major Events 2001 • Abbott acquires the 1982 pharmaceutical business of BASF, including the • Abbott is listed as a global operations of Knoll 1962 public limited company in Pharmaceuticals. 5 Pakistan. Abbott opens its first 1948 Manufacturing facility in Karachi, Pakistan. Abbott starte
Slide 6: Financial Performance Snapshot
Financial Performance Snapshot
Slide 7: Financial metrics – Key Ratios
Financial metrics – Key Ratios Ratios Units 2021 2022 2023 2024 2025 Gross profit margin % 37.8% 29.5% 21.3% 29.0% 35.1% Net profit margin % 14.0% 6.1% 0.5% 7.7% 10.6% Return on Assets % 20.9% 8.9% 0.7% 13.9% 17.02% Basic / Diluted earnings per share Rs. 60.9 30.69 2.67 53.46 81.37 Return on equity
Slide 8: Financial metrics – Profitability Ratios
Financial metrics – Profitability Ratios
Slide 9: Statement of Profit and Loss
Statement of Profit and Loss 2020 2021 2022 2023 2024 2025 Rupees in Million Net sales 35,283 42,570 49,258 55,475 68,177 75,398 Cost of sales 23,437 26,495 34,732 43,658 48,439 48,946 Gross Profit 11,846 16,075 14,526 11,817 19,738 26,452 Selling and distribution expenses 4,936 6,569 7,038 8,040 9,
Slide 10: Financial metrics – Statement of Profit and loss
Financial metrics – Statement of Profit and loss
Slide 11: Statement of Financial Position
Statement of Financial Position 2020 2021 2022 2023 2024 2025 Rupees in Million Non Current Assets 9,213 10,135 12,091 13,494 14,389 15,823 Property, plant and equipment 9,070 10,006 11,989 13,375 14,253 15,636 Intangible asset 66 49 27 13 1 1 Other Non-Current Assets 77 80 75 106 135 186 Current As
Slide 12: Financial metrics - Statement of Financial Position
Financial metrics - Statement of Financial Position 12
Slide 13: Business Performance
Business Performance = ABBOTTE—=
Slide 14: Key resources and capabilities of the Company; Key Performance Indicators
Key resources and Key Performance Indicators capabilities of the Company 14
Slide 15: Our Segments
Our Segments Established Pharmaceuticals • Advancing Access to Trusted, High Quality Therapeutic and Preventive Healthcare Products Nutrition • Science-based nutrition to support the growth, health, and wellness of people at every stage of life Diagnostics • Customised, scalable solutions improving
Slide 16: Segmental Overview
Segmental Overview Segment wise contribution to the Total Revenue and Total Profit of the company 16
Slide 17: Geographical Overview
Geographical Overview NET SALES - EXPORTS Afghanistan Sri Lanka Bangladesh Switzerland Net Sales - Exports 2025 2024 ----------- (Rupees '000) ------- Afghanistan 1,552,609 1,461,505 37% Sri Lanka 44,262 35,922 Bangladesh 60,035 60,125 Switzerland 994,863 1,200,616 2,651,769 2,758,168 59% 2% 2%
Slide 18: Awards and Recognition
Awards and Recognition Cc) ABBOTT
Slide 19: Awards and Recognitions
Awards and Recognitions Water Stewardship Management Alliance for Water Stewardship Award – OICCI Climate (AWS) Certification – 2025 Excellence Award 2025 22nd Annual Environmental Corporate Social Responsibility Excellence Award – NFEH Awards – NFEH Abbott Pakistan secures First Place at the 40th C
Slide 20: Future Outlook
Future Outlook
Slide 21: Risk and Opportunities
Risk and Opportunities Market & Growth Forward-Looking Outlook •Positive industry outlook •Quality products & innovation focus •Driven by demographics & awareness •Sustainable growth & wider patient access •Investments in brand building, supply chain & digital •Leverage best practices capabilities R
Slide 22: Sica
Sica Cc) ABBOTT
Abbott Laboratories Pakistan — Investor Presentation (May 2026) on 6ix